 Akari Therapeutics Plc NASDAQ: AKTX announces new data from PASylated nomacopan published in the journal CELLS. In a non-infectious allergic uveitis animal model, PAS-nomacopan reduced VEGF by more than 50 compared to saline control, equivalent to the inhibition caused by an anti-VEGF antibody. 